« Return to News | Drug Sponsors

Pfizer still seeking CROs for U.K. site

Thursday, June 2, 2011 11:21 AM

Pfizer continues to search for CROs to occupy a U.K. site, but the local council is disappointed by the lack of government action.

Pfizer plans to exit the Sandwich site by the end of 2012, affecting 2,400 employees and 900 on-site contractors. Another 10,000 jobs are under threat at other local businesses, and the council hopes Pfizer can avoid adding to this by moving staff to CROs.

“Pfizer is progressing commercially confidential negotiations with potential CROs and exploring the potential for small spin-out companies to develop from the site,” said the Sandwich Economic Development Task Force.

Moving Pfizer staff and assets to CROs is viewed by the task sorce as the first phase of a five-step transition process. With a core of CROs in place, the task force will look to attract startups and large-scale occupiers to take on whole buildings.

To support this process, the task force made a number of proposals to the government but has been disappointed by the lack of action. Pfizer has already sent ‘at risk of redundancy’ notices to 900 staff, making the next month critical for the future of the Sandwich site.

“If there is to be some form of state aid, it is needed now,” said the task force. Incentives could be used to encourage CROs to occupy the site.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.